Pediatric Hearing Loss (The Deaf Child)
High-Yield Revision Notes for NEET PG / NEXT
Hearing impairment in infants and children significantly impacts speech, language acquisition, and cognitive development. Early identification via Universal Newborn Hearing Screening (UNHS) and structured intervention are paramount.
1. Etiology of Pediatric Hearing Loss
Causes are broadly classified into Congenital (Genetic/Non-genetic) and Acquired categories.
| Category | Specific Causes & High-Yield Associations |
|---|---|
| Genetic Congenital (50% of congenital cases) |
• Nonsyndromic (70-80%): Most commonly **Autosomal Recessive (DFNB1)** involving mutations in the GJB2 gene which encodes the gap junction protein Connexin 26. • Syndromic (20-30%): – Waardenburg Syndrome: AD; SNHL, heterochromia iridis, white forelock, dystopia canthorum. – Pendred Syndrome: AR; SNHL, multinodular goiter, chloride-iodide transport defect (SLC26A4 gene). – Jervell and Lange-Nielsen Syndrome: AR; profound SNHL, **prolonged QT interval**, high risk of sudden death. – Usher Syndrome: AR; SNHL paired with progressive retinitis pigmentosa. |
| Non-Genetic Congenital (Prenatal / Perinatal) |
• TORCH Infections: **Cytomegalovirus (CMV)** is the most common non-genetic cause of congenital SNHL (characteristically progressive). Congenital Rubella presents with a “cookie-bite” audiogram configuration. • Perinatal Stressors: Severe neonatal hyperbilirubinemia (causes kernicterus affecting the cochlear nuclei, leading to Auditory Neuropathy Spectrum Disorder), prematurity (birth weight less than 1500g), and prolonged neonatal hypoxia. |
| Acquired (Infancy / Childhood) |
• Infectious: **Bacterial Meningitis** (e.g., S. pneumoniae) is a major cause of acquired profound SNHL due to **suppurative labyrinthitis ossificans** (ossification of the cochlea). Mumps causes sudden, severe, unilateral SNHL. • Conductive Blocks: **Otitis Media with Effusion (OME / Glue Ear)** is the single most common cause of acquired conductive hearing loss in toddlers. Chronic adenoid hypertrophy drives eustachian tube dysfunction. |
2. Diagnostic Evaluation Protocol
Universal Newborn Hearing Screening relies on the high-yield **1-3-6 Rule**: Screening by **1 month**, Diagnostic confirmation by **3 months**, and Rehabilitation enrollment by **6 months**.
Objective Electrophysiologic Screening & Testing Matrix
- Otoacoustic Emissions (OAE): Evaluates the metabolic health and integrity of the **outer hair cells** of the cochlea. Quick, non-invasive screening tool. *Drawback:* Yields a “false refer” result if the external auditory canal is occluded with vernix or fluid, and misses retrocochlear pathologies.
- Automated Auditory Brainstem Response (AABR): Screening variant using a fixed click stimulus. Measures neural synchronization up to the brainstem. Ideal for NICU graduates to rule out auditory neuropathy.
- Diagnostic Auditory Brainstem Response (ABR / BERA): The gold standard for quantifying hearing thresholds objectively in infants unable to participate in behavioral testing. Measures five distinct waveforms (Waves I to V); **Wave V** tracking down to the lowest sound intensity determines the absolute hearing threshold.
- Auditory Steady-State Response (ASSR): Provides frequency-specific threshold estimations across low, mid, and high frequencies simultaneously, aiding precise hearing aid configuration in severe-to-profound losses.
- Tympanometry: Evaluates middle ear compliance. Crucial note: Newborns under 6 months have highly compliant ear canal walls; hence, a **1000 Hz probe tone** must be utilized instead of the standard 226 Hz probe tone to avoid false normal Type A curves.
Age-Appropriate Behavioral Testing
- 0 to 6 Months: Behavioral Observation Audiometry (BOA)—tracks unconditioned reflex responses like the Moro reflex, eye-blinking, or cessation of sucking. Highly subjective.
- 6 Months to 2.5 Years: Visual Reinforcement Audiometry (VRA)—conditions the child to turn towards a sound source by reinforcing the action with an animated lit toy.
- 2.5 Years to 5 Years: Conditioned Play Audiometry (CPA)—turns threshold testing into a game (e.g., dropping a peg into a pegboard every time a tone is introduced).
3. Comprehensive Management Strategy
Rehabilitation options match the underlying anatomical site and severity of the hearing barrier:
Medical & Surgical Interventions
- Myringotomy with Grommet Insertion: The treatment of choice for chronic Otitis Media with Effusion demonstrating structural changes or speech delay. Restores a normal conductive mechanism instantly.
- Bone-Anchored Hearing Aid (BAHA): Indicated for severe, irreversible bilateral conductive or mixed hearing losses secondary to congenital anomalies such as **bilateral microtia or aural atresia** (where standard air-conduction molds cannot be inserted).
Sensory Amplification Protocol
- Digital Hearing Aids: Initiated as early as **6 months of age** once severe bilateral SNHL is confirmed. High-powered behind-the-ear (BTE) digital models are standard. They amplify residual hearing to stimulate the auditory cortex and keep auditory pathways viable.
Cochlear Implantation (High-Yield Board Criteria)
- Indication: Bilateral **severe-to-profound Sensorineural Hearing Loss** deriving minimal to no functional benefit from optimal digital hearing aids after a structured 3-to-6-month trial.
- Optimal Age window: Recommended as early as **9 to 12 months of age** to maximize neuroplastic benefits during critical language development windows.
- Mechanism: Bypasses damaged cochlear hair cells entirely by surgically threading an electrode array directly into the **scala tympani** via the round window, providing direct electrical stimulation to the spiral ganglion cells of the cochlear nerve.
- Critical Prerequisite Imaging: High-Resolution CT and thin-slice T2 MRI of the inner ear are mandatory to rule out **Michel aplasia** (complete absence of the inner ear structures) or **cochlear nerve aplasia**, which are absolute contraindications, and to screen for post-meningitis labyrinthitis ossificans.
- Auditory-Verbal Therapy (AVT): Intensive post-implantation speech and listening habilitation program mandatory for developing spoken language proficiency.